Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-7: BI 764532 plus platinum-etoposide in first-line NEC
jRCT2031230511Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of obrixtamig in neuroendocrine carcinoma (NEC), large cell neuroendocrine carcinoma (LCNEC) and neuroendocrine carcinoma of unknown primary origin (CUP-NEC), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities in Part A (MTD evaluation period) and Dose-limiting toxicities in Part B (on-treatment period). Started Dec 2023; status: recruiting.
02
Drugs
obrixtamig
03
Conditions
neuroendocrine carcinoma (NEC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine carcinoma of unknown primary origin (CUP-NEC)
Beyond the preview
Go deeper on jRCT2031230511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230511.